Mr. Lehr is the Co-founder and CEO of Context Therapeutics. In addition, Mr. Lehr is a member of the Scientific Advisory Board of Integral Molecular, an antibody discovery company. Previously, Martin was part of the founding team at Osage University Partners, a venture capital fund focused on academic spinouts from leading research institutions. At Osage, Martin focused on early stage oncology and rare disease opportunities. Prior to Osage, Martin conducted research at the Sloan Kettering Institute in DNA repair and at the Children’s Hospital of Philadelphia in thrombosis and hemostasis. In addition to his role at Context, Martin is the Director of Philly BioBreak, a biotech executive peer group with over 2,500 active members across the United States. He holds an M.A. in Biotechnology from Columbia University and a B.A. in Economics from the University of Pennsylvania.
Scott Applebaum is a high-impact, strategic executive with deep global experience and demonstrated operational success leading legal, commercial, and regulatory functions for small and large life sciences companies. Scott joins Context Therapeutics from Vitae Pharmaceuticals, where he was General Counsel & Corporate Secretary at the time of its sale to Allergan. Prior to Vitae, Scott was Chief Legal Officer & Corporate Secretary for Medgenics, Inc., a clinical stage, publicly traded biotech. Scott previously spent 10 years as Senior Vice President at Shire Pharmaceuticals, where he led the strategy and execution of three key functions – commercial, legal, and regulatory. Before joining Shire, Scott spent seven years in progressive legal positions at Bristol-Myers Squibb, and he began his career as an Associate in the Corporate Tax Department at Dechert LLP.
Scott earned a Juris Doctor from Stanford Law School, where he was an editor of the law review, and a B.S. in Economics from the Wharton School, University of Pennsylvania. He is a member of the Pennsylvania and New Jersey bars, and is a certified public accountant.
Mr. Morris is an accomplished senior finance executive who has spent over 20 years in the life science industry, most recently as Chief Financial Officer of Vitae Pharmaceuticals, which was acquired by Allergan PLC for $639 million in November 2016. In this capacity, he led the company’s multiple public offerings and raised over $130 million. Prior to Vitae, Rich spent 12 years at ViroPharma Incorporated. He was Vice President - Financial and Strategic Planning when the company was acquired for $4.2 billion by Shire Pharmaceuticals. In addition to leading finance teams in the US, Rich provided finance leadership for multiple product launches, product in-licensing and acquisitions and oversight for European operations and was a member of the company’s European Business Unit Board and of the International Business Unit Board.
Rich began his career with KPMG, LLP in their Healthcare and Life Science practice. Rich holds a Bachelor of Science degree in Accounting from Saint Joseph’s University in Philadelphia and is a Certified Public Accountant in the state of Pennsylvania.
Dr. Kim is Co-founder and Head of Sigma1 Program. In addition, Felix currently serves as a Member of the Sidney Kimmel Cancer Center at Thomas Jefferson University, Assistant Professor at Drexel University, and Secretary/Treasurer of the Translational and Clinical Pharmacology division of the American Society for Pharmacology and Experimental Therapeutics (ASPET). He is an expert in the pharmacology and biology of Sigma1 in cancer and in Sigma1 drug discovery. He has produced novel technologies and small molecule compounds used by scientists around the world to elucidate the role of Sigma1 in disease. He holds a BS in Biochemistry & Cell Biology from the University of California at San Diego, a PhD in Biochemistry from the Université de Montpellier (France) for work performed at the Centre National de la Recherche Scientifique, and performed a post-doctoral fellowship in the Molecular Pharmacology & Chemistry Program at Memorial Sloan Kettering Cancer Center.
Dr. Tasir Haque is Head of Chemistry at Context Therapeutics. Prior to joining Context, Tas was a Principal Scientist in Immunology Chemistry at Bristol-Myers Squibb, where he focused on advancing small molecule programs to IND status. His background at BMS includes drug discovery programs in several therapeutic areas including Oncology, Metabolic Diseases, and Cardiovascular Diseases. Tas has extensive experience with both small molecule and linear and cyclic peptide research. Earlier in his career, Tas was a member of the Directed Parallel Synthesis medicinal chemistry team at DuPont Pharmaceuticals, where he focused on Anti-Infectives. Tas is an inventor on multiple patents and has written and reviewed articles in several peer-reviewed journals. He holds a B.S. in Chemistry from the University of Michigan, a Ph.D. in Organic Chemistry from the University of Wisconsin, and was an NIH postdoctoral fellow at the University of California, Berkeley.
Dr. Lala has 20 years of drug discovery experience at a strategic and operational level in large and small pharmaceutical companies. Before Context he was Executive Director, Biology at Vitae Pharmaceuticals (affiliate of Allergan Inc.) where he played a key role in advancing seven compounds into clinical studies (Phase I/II) for multiple indications. He was also responsible for building and executing translational biomarker approaches for human proof of mechanism studies. Before Vitae, he was Associate Director at Pfizer where he led an anti-fibrosis program leading to a clinical candidate and demonstrating the translatability of preclinical fibrotic biomarkers in the clinic. Prior to that he was a Group Leader at Pharmacia where he created a drug discovery platform to initiate new programs across different therapeutic areas. Before that he worked at Ligand Pharmaceuticals focusing on nuclear receptors as drug targets. Dr. Lala earned his Ph.D. in Cell and Molecular Biology from Augusta University. He was awarded a Howard Hughes Medical Institute (HHMI) fellowship to carry out post-doctoral training at Duke University Medical Center.
Mr. Beck is a pharmaceutical leader with a proven track record in strategy execution. His 30-year career spans a spectrum of disciplines including: program/resource management; merger and acquisition integration; and cross-functional team leadership. He joins Context Therapeutics from Aevi Genomics, where he was the VP of Program Management. Previously, Mr. Beck was VP of Schedule and Resource Decision Analytics at Shire Pharmaceuticals, and created Shire’s first global project management and resource capacity planning capability. Adding to the ten years of pharmaceutical experience at Shire, Mr. Beck envisioned, created and led global project and resource management organizations at Merck and Co, Astra Pharmaceuticals and AstraZeneca Inc. Earlier in his career, Mr. Beck forged his project management foundation at GE Aerospace as a project scheduler.
Mr. Beck holds a B.S. Business Administration degree, from Drexel University and an MBA from Pennsylvania State University.